Alkem Foundation, IIT Bombay to Set Up Advanced Research Centre
ECONOMY & POLICY

Alkem Foundation, IIT Bombay to Set Up Advanced Research Centre

Mumbai, November 3, 2025 — Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, has announced a strategic collaboration with the Indian Institute of Technology Bombay (IIT Bombay) to establish a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines.

Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project.

The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem.

The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health.

Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities.

Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.”

Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Mumbai, November 3, 2025 — Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, has announced a strategic collaboration with the Indian Institute of Technology Bombay (IIT Bombay) to establish a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines. Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project. The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem. The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health. Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities. Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.” Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code